ACXP News and Press, Acurx Pharmaceuticals Inc. From 05/11/22

Acurx Pharmaceuticals press release (NASDAQ:ACXP): Q1 GAAP EPS of -$0.26 beats by $0.07. Cash balance of $1.08M  as of March31, 2022 For further details see: Acurx Pharmaceuticals GAAP EPS of -$0.26 beats by $0.07

Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , May 11, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical sta...

Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , April 29, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acur...

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2021 Results Conference Call March 17, 2022 08:30 AM ET Company Participants David Luci - President and CEO Rob Shawah - Co-Founder and CFO Conference Call Participants Jason McCarthy - Maxim Group Presentation Operator Greetings, and welcome to the Acurx...

Acurx Pharmaceuticals press release (NASDAQ:ACXP): FY GAAP EPS of -$1.49 beats by $0.20. Cash balance of $12.96M as of December 31, 2021 For further details see: Acurx Pharmaceuticals GAAP EPS of -$1.49 beats by $0.20

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , March 17, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), ...

Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT PR Newswire STATEN ISLAND, N.Y. , March 16, 2022 /PRNewswire/ -- Acurx Pharmaceuticals...

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update Enrollment has started in Phase 2b trial of Ibezapolstat in Patients with C. difficile Infection PR Newswire STATEN ISLAND, N.Y. , March 7, 2022 /...

Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases PR Newswire STATEN ISLAND, N.Y. , Feb. 7, 2022 /PRNewswire/ -- Publication of study presents: Clinical results of 10 of 10 ...

Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) - First patient enrolled in Phase 2b comparative trial segment vs vancomycin, current standard of care - Previously completed Ph...